



CENTER FOR IMPROVING  
VALUE IN HEALTH CARE

## Colorado All Payer Claims Database Data Release Application Part I

Part I of the Data Release Application should be used to submit background information related to your organization's request for data from the Colorado All Payer Claims Database (CO APCD). This information will help the Center for Improving Value in Health Care (CIVHC), the Administrator of the CO APCD, understand the questions you are trying to answer with your data request and assist us in helping you through the data request process. All CO APCD data requests go through a careful review and approval process and involve a licensing fee. CIVHC has a team of Health Data Solutions Consultant who will work closely with you throughout the data request process.

Prior to completing the questions below, please review the information on requesting data and reports located at <https://www.civhc.org/get-data/non-public-data/>.

Project Information	
<b>Project Title:</b>	<b>23.69 Pediatric Polypharmacy, Healthcare Utilization, and Costs Among Colorado Children</b>
<b>Date:</b>	6/28/2023
<b>Organization Requesting Data:</b>	University of Colorado Denver
<b>Contact Person:</b>	James A. Feinstein, MD, MPH
<b>Title:</b>	Associate Professor
<b>E-mail:</b>	<a href="mailto:James.Feinstein@cuanschutz.edu">James.Feinstein@cuanschutz.edu</a>
<b>Phone Number:</b>	(303) 724-4186 (office) / (303) 803-2223 (cell)
<b>Address:</b>	ACCORDS - School of Medicine, CU-Anschutz 1890 North Revere Court, Suite 300 Aurora, CO 80045
<b>CIVHC Contact:</b>	Eddy Costa

### Project Purpose

- I. Describe your project and project goals/objectives in detail.

Polypharmacy is an umbrella term to describe the simultaneous use of multiple medicines by a patient for their conditions. Most commonly it is defined as regularly taking five or more medicines but definitions vary in where they draw the line for the minimum number of drugs.

Optimal health for children with medical complexity (CMC) often depends on exposure to outpatient pediatric polypharmacy ( $\geq 5$  concurrent medications), as work by this PI and study team has shown. In analogous adult populations, outpatient polypharmacy is associated with increased risk for morbidity, healthcare utilization, and costs. In 2021, the Joint Commission Sentinel Event Alert highlighted the dire need for "additional research on interventions to reduce pediatric medication errors, especially in emergency departments, ambulatory clinics and home environments." This PI and study team have NIH/AHRQ funding (R01HS028979) to study patient-level clinical interventions to improve medication safety in children with polypharmacy. However, subsequent implementation and evaluation of these interventions at the population level in Colorado will require knowing the answers to several important questions: How many children are exposed to polypharmacy who might benefit from improved medication

management? Where do these children receive most of their care (e.g., inpatient versus outpatient), so that we can target interventions to the appropriate clinical setting? How much does polypharmacy cost, so that we can evaluate potential opportunities and targets to improve value? Prior efforts by this PI to study these questions have been limited to Colorado Medicaid claims only (CMS Data-RESDAC), leading to reduced samples when patients changed insurance payors in Colorado. The COAPCD Data works to minimize this risk by tracking individual patients through their system, even if patients change insurance payors. Thus, we propose a more definitive, up-to-date, and comprehensive set of data and analysis of pediatric polypharmacy in the State of Colorado using the APCD to establish Colorado-specific population-level benchmarks for pediatric polypharmacy and associated healthcare utilization and costs.

## **METHODOLOGY**

This is a retrospective cohort study of the Colorado All-Payer Claims Database between 2017 and 2022. We will describe the demographics and clinical characteristics of the overall sample, including age, sex, race and/or ethnicity, and Medicaid eligibility. We will identify medical complexity using the complex chronic conditions (CCCs) system version to identify children with CCCs known to be associated with high morbidity and resource use.

SA1: We will measure maximal annual exposure to polypharmacy by counting the number of unique concurrent prescriptions for each patient day during the contributed year.<sup>11</sup> To do so, we will create arrays of prescription data based on each filled and completed prescription's start date and quantity dispensed. At the level of each patient, we will collapse the data such that we sum the overlapping number of prescriptions for each day of the contributed patient-year.

SA2: We will measure healthcare utilization associated with polypharmacy in the most recent year of data.<sup>2</sup> We will calculate healthcare use associated with polypharmacy by assessing 7 mutually exclusive service groupings: primary care, outpatient specialty, emergency department (ED), inpatient, mental health (inpatient and outpatient), pharmacy, and laboratory and/or radiographic testing.

SA3: We will measure healthcare costs associated with polypharmacy in the most recent year of data.<sup>2</sup> We will calculate healthcare costs associated with polypharmacy by assessing 7 mutually exclusive service groupings: primary care, outpatient specialty, emergency department (ED), inpatient, mental health (inpatient and outpatient), pharmacy, and laboratory and/or radiographic testing.

What specific research question(s) are you trying to answer or problem(s) are you trying to solve with this data request? (Please list and number the individual questions.)

**Hypothesis:** Among Colorado children (0-21yo):

1. Quantify the annual prevalence of polypharmacy ( $\geq 5$  medications)
  - The prevalence of polypharmacy will increase annually during the study period
2. Describe healthcare utilization associated with polypharmacy
  - $\geq 50\%$  of healthcare contact days will be in outpatient setting
3. Calculate healthcare costs (total and pharmacy-specific) associated with polypharmacy
  - Pharmacy spending will be costliest service line category

2. How will this project benefit Colorado or Colorado residents? (This is a statutory requirement for all non-public releases of CO APCD data. Contributions to the generalizable knowledge is not sufficient.)

Implementation and evaluation of medication safety interventions at the population level in Colorado will require knowing the answers to several important questions: How many Colorado children are exposed to polypharmacy? Where do these Colorado children receive most of their care, so that we can target interventions to the appropriate clinical setting? How much does polypharmacy cost Coloradans, so that we can evaluate opportunities to improve value? Thus, we propose a comprehensive analysis of Colorado All-Payer Claims Database to establish Colorado-specific population-level benchmarks for pediatric polypharmacy and associated healthcare utilization and costs.

3. Describe how the project will meet one or more of the Triple Aim criteria below.
- Improve the patient experience of care (including quality and satisfaction)
  - Improve the health of populations
  - Reduce the per capita cost of health care

Pediatric polypharmacy (defined as  $\geq 5$  concurrent medications) is a major public health problem with high prevalence among the priority population of children with medical complexity. Pediatric polypharmacy is necessary for symptom and disease management, but major opportunities exist to improve outpatient medication management, safety, and value. A more comprehensive understanding of pediatric polypharmacy in the State of Colorado has the potential to have an enormous impact on the public health of CMC by preventing medication-related safety issues, the attendant morbidity, and the associated costs.

4. The State of Colorado and CIVHC are committed to ensuring everyone, regardless of demographics, has access to the care they need when they need it. How might your project contribute to that?

Colorado parents administer complex polypharmacy regimens at home and some parents administer a median of 30 doses of medication per day. Ultimately, interventions to manage polypharmacy must be acceptable to and inclusive of Colorado parents from all levels of health literacy and should minimize additional caregiving burdens.

5. Can CIVHC publicly share your organization's' name in the work we do to promote our Change Agent clients in our [Change Agent Index?](#) ☒ Yes ☐ No

**Type of Output Requested:** Select the level of detail that you are requesting. If you are unsure, please contact us at [ColoradoAPCD@civhc.org](mailto:ColoradoAPCD@civhc.org).

- ☐ Standard De-identified Data Set  
☒ Limited Data Set  
☐ Identified Data Set  
☐ Standard Report  
☐ Custom Report

**Lines of Business:** Which payers do you need for your project purpose?

- ☒ **Commercial Payers (Includes Medicare Advantage)**
- ☒ **Health First Colorado (Colorado's Medicaid Program)** – Note: Medicaid only data requests must be reviewed by the Colorado Department of Health Care Policy and Financing (HCPF) to ensure alignment with administration of the Medicaid program as required by federal law.
- ☐ **Medicare Fee For Service (FFS)** – Note: Data requests for Medicare FFS are only available for authorized users for research purposes and must be approved by HCPF.

**Years Requested:** What years of claims do you need to meet your project purpose?

- |  |  |
|--|--|
| <input type="checkbox"/> 2012            | <input checked="" type="checkbox"/> 2018 |
| <input type="checkbox"/> 2013            | <input checked="" type="checkbox"/> 2019 |
| <input type="checkbox"/> 2014            | <input checked="" type="checkbox"/> 2020 |
| <input type="checkbox"/> 2015            | <input checked="" type="checkbox"/> 2021 |
| <input type="checkbox"/> 2016            | <input checked="" type="checkbox"/> 2022 |
| <input checked="" type="checkbox"/> 2017 |  |

**Data Needs**

The following questions are related to Protected Health Information (PHI) to determine if you need a Limited Data Set or an Identifiable Data Set. The Data Elements Dictionary detailing the fields available for both types of data can be found at <https://www.civhc.org/get-data/non-public-data/>. **Note that any data request including PHI will need Part 2 of the Application and approval by the Data Release Review Committee.**

1. Do you need patient-specific dates (e.g., dates of service or DOB) or 5 digit zip code? If so, this is a request for a **Limited Data Set**.  
☒ Yes   ☐ No (**We are requesting dates of service – DOS**)
2. Do you need direct patient identifiers such as name, address, or city? If so, this is a request for an **Identifiable Data Set** (requires IRB approval).  
☐ Yes   ☒ No

# Colorado All Payer Claims Database Data Release Application Part 2

(Limited Data Sets and Fully Identifiable Data Sets ONLY)

Project Information from Part I of Application	
<b>Project Title:</b>	23.69 Pediatric Polypharmacy, Healthcare Utilization, and Costs Among Colorado Children
<b>Date:</b>	6-28-23
<b>Organization Requesting Data:</b>	University of Colorado Denver

The CO APCD is committed to protecting the privacy and security of Colorado's claims data. The CO APCD will limit the use of the data to purposes permitted under applicable laws, including APCD Statute/Rule, HIPAA/HITECH, and Antitrust laws, to information reasonably necessary to accomplish the project purpose as described in this Application. Under HIPAA, PHI may only be released in limited circumstances for public health (public health agency), health care operations, and research purposes under the terms of a HIPAA compliant data use agreement (DUA).

Any requestor receiving a CO APCD data set, must submit to APCD Administrator a Data Management Plan that outlines data security and data management policies and procedures to safeguard the data. This Data Management Plan must be approved by APCD Administrator prior to any data release.

**1. Data Element Selection Member-level Detail** – Do you need member level PHI data for your project purpose? In keeping with the minimum necessary standard established under HIPAA, CO APCD policy is to release only those data elements that are required to complete your project.

- ☐ No
- ☒ Yes (Justification must be provided for each)
  - ☐ 3-digit zip
  - ☐ Name (first, last, middle)
  - ☐ Street Address
  - ☐ City
  - ☐ Zip
  - ☒ **DOB (To calculate age at dates of service)**
  - ☐ Gender

**2. Claim-Level Detail** – Include specific diagnosis codes, CPT4, CDT, ICD9 or I0, APR-DRG, or revenue codes in an attachment. **AGES 0-21**

- ☐ No
- ☒ Yes (Justification must be provided for each)
  - ☒ Age at time of service (To stratify analysis by age categories)
  - ☐ Age at year end
  - ☒ Diagnosis (To identify the presence of medical complexity)
  - ☒ Procedure/Revenue Code (To identify the presence of medical complexity)

**3. Claim Type** – What types of claims do you need for your project purpose?

- ☒ Inpatient (**IP**) – Related to individuals who receive care in hospital settings
- ☒ Outpatient (**OP**) – Related to an individual receiving medical treatment in any setting other than a hospital admission (i.e. ambulatory surgery center; doctor's office, imaging center, emergency room, home health, etc.)
- ☒ Professional (**PROF**) – Related to medical procedures within professional settings (e.g. physician office, imaging center, etc.) and clinics
- ☒ Pharmacy (**PC**) – Related to prescriptions with an 11-digit National Drug Code
- ☒ Dental (**D**) – Related to individuals receiving dental care in any dental setting

**4. Provider-Level Detail** – Do you need claims limited to specific providers or provider type(s) for your project purpose? (Provider IDs, locations, hospitals, medical groups, etc.)

- ☐ No
- ☒ Yes (check all that apply)
  - ☐ Facilities (please specify) Click or tap here to enter text.
  - ☐ Professionals
  - ☒ Provider Taxonomy - Specialty Designations
  - ☐ National Provider Identifier
  - ☐ Other (please specify) Click or tap here to enter text.

**5. Provider Geography** – Do you need provider geography or location data?

- ☐ No
- ☒ Yes (check all that apply)
  - ☐ Provider location address
  - ☐ Provider Zip 3
  - ☒ Provider Health Statistic Region <http://www.cohid.dphe.state.co.us/brfssdata.html>
  - ☐ Provider County
  - ☐ Provider Zip 5
  - ☐ Other (please specify) Click or tap here to enter text.

**6. Payer-Specific Details** – Do you need specific named payer details? (only available for authorized requestors)

- ☒ No
- ☐ Yes

**7. Payment Type** – Which elements of cost data do you need to support your project purpose?

- ☒ Charged Amount
- ☒ Plan Paid Amount
- ☒ Member Liability, i.e., amount the member is responsible for
  - ☒ Coinsurance
  - ☒ Deductible
  - ☒ Copay
- ☒ Total Allowed Amount – (summation of plan paid and member liability)
- ☒ Prepaid Amount – (to be considered for capitated payment plans only)

## 8. Data Element Selection

If you have not already done so, complete the Data Element Dictionary (DED) to identify the specific data elements that are required for this project.

## 9. Data Source Linkage – Will you link the CO APCD data to another data source?

- ☒ No
- ☐ Yes. If yes, please answer the following questions.
- What is the other data source or sources you plan to link CO APCD data with?
  - Which CO APCD identifying data elements will be used to perform the linkage?
  - Once the linkage is made, what non-CO APCD data elements will appear in the new linked file?

## 10. Institutional Review Board – Have all necessary approvals been obtained (e.g., IRB or Privacy Board approval)?

- ☐ No or N/A, reason: Click or tap here to enter text.
- ☐ In progress. Anticipated approval date:
- ☒ Yes. If so please provide copy. **Received by CIVHC and approved 4-23-23**

## 11. Distribution of the Report or Product – Requires review before publication

If you are producing a report for publication in any medium (print, electronic, lecture, slides, etc.) the CO APCD Administrator must review the report prior to public release. This requirement is further spelled out in the Data Use Agreement. The CO APCD Administrator will review the report for compliance with CMS cell suppression rules, risk of inferential identification, and consistency with the purpose and methodology described in this Application. Do you acknowledge this requirement?

- ☐ No
- ☒ Yes

## 12. Project Schedule:

Proposed Project Start Date:	7/25/2023
Project End Date:	5/31/2025
Proposed Publication or Release Date:	5/31/2025
Data Destruction Period:	All data must be destroyed within 30 days of the project end date and data destruction certificate returned to CIVHC at <a href="mailto:datacompliance@civhc.org">datacompliance@civhc.org</a> . The Data Destruction Certificate form can be found at <a href="https://www.civhc.org/get-data/non-public-data/">https://www.civhc.org/get-data/non-public-data/</a> .

### Statistical Considerations

We will use descriptive statistics to describe demographics and clinical characteristics of the study population, their exposure to polypharmacy, and the associated healthcare utilization and costs. For H1, we will test trends in annual exposure to polypharmacy using a test for linear trend over the 6-year study period. For H2, we will report the percentage of subjects and the days per subject using each service grouping associated with polypharmacy.<sup>2</sup> For H3, we will report the total spending and the median per-member per-year (PMPY) spending by each

service grouping associated with polypharmacy.<sup>2</sup> Analyses will be performed by using Stata 17. P values <.05 will be considered statistically significant.

### **Summarize Knowledge to be Gained**

Implementation and evaluation of medication safety interventions at the population level in Colorado will require knowing the answers to several important questions: How many Colorado children are exposed to polypharmacy? Where do these Colorado children receive most of their care, so that we can target interventions to the appropriate clinical setting? How much does polypharmacy cost Coloradans, so that we can evaluate opportunities to improve value? Thus, we propose a comprehensive analysis of Colorado All-Payer Claims Database to establish Colorado-specific population-level benchmarks for pediatric polypharmacy and associated healthcare utilization and costs.



STUDY PROTOCOL

Open Access



# A coordinated approach for managing polypharmacy among children with medical complexity: rationale and design of the Pediatric Medication Therapy Management (pMTM) randomized controlled trial

Lucas E. Orth<sup>1,2</sup> , Chris Feudtner<sup>3,4</sup> , Allison Kempe<sup>5,6</sup>, Megan A. Morris<sup>5,7</sup>, Kathryn L. Colborn<sup>5,8,9</sup>, R. Mark Gritz<sup>5,7</sup>, Sunny A. Linnebur<sup>1</sup> , Anowara Begum<sup>5</sup> and James A. Feinstein<sup>5,6\*</sup>

## Abstract

**Background** Children with medical complexity (CMC) often rely upon the use of multiple medications to sustain quality of life and control substantial symptom burden. Pediatric polypharmacy ( $\geq 5$  concurrent medications) is prevalent and increases the risk of medication-related problems (MRPs). Although MRPs are associated with pediatric morbidity and healthcare utilization, polypharmacy is infrequently assessed during routine clinical care for CMC. The aim of this randomized controlled trial is to determine if a structured pharmacist-led Pediatric Medication Therapy Management (pMTM) intervention reduces MRP counts, as well as the secondary outcomes of symptom burden and acute healthcare utilization.

**Methods** This is a hybrid type 2 randomized controlled trial assessing the effectiveness of pMTM compared to usual care in a large, patient-centered medical home for CMC. Eligible patients include all children ages 2–18 years old, with  $\geq 1$  complex chronic condition, and with  $\geq 5$  active medications, as well as their English-speaking primary caregivers. Child participants and their primary parental caregivers will be randomized to pMTM or usual care before a non-acute primary care visit and followed for 90 days. Using generalized linear models, the overall effectiveness of the intervention will be evaluated using total MRP counts at 90 days following pMTM intervention or usual care visit. Following attrition, a total of 296 CMC will contribute measurements at 90 days, which provides  $> 90\%$  power to detect a clinically significant 1.0 reduction in total MRPs with an alpha level of 0.05. Secondary outcomes include Parent-Reported Outcomes of Symptoms (PRO-Sx) symptom burden scores and acute healthcare visit counts. Program replication costs will be assessed using time-driven activity-based scoring.

**Discussion** This pMTM trial aims to test hypotheses that a patient-centered medication optimization intervention delivered by pediatric pharmacists will result in lower MRP counts, stable or improved symptom burdens, and fewer cumulative acute healthcare encounters at 90 days following pMTM compared to usual care. The results of this trial will be used to quantify medication-related outcomes, safety, and value for a high-utilization group of CMC, and

\*Correspondence:  
James A. Feinstein  
james.feinstein@cuanschutz.edu  
Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

outcomes may elucidate the role of integrated pharmacist services as a key component of outpatient complex care programs for this priority pediatric population.

**Trial Registration** This trial was prospectively registered at clinicaltrials.gov (NCT05761847) on Feb 25, 2023.

**Keywords** Pediatrics, Children with medical complexity, Polypharmacy, Deprescribing, Medication safety, Adverse drug events

## Background

### Pediatric polypharmacy and children with medical complexity

Pediatric polypharmacy (defined as concurrent use of  $\geq 5$  medications) is a major public health problem with high prevalence among the priority population of children with medical complexity (CMC) [1]. Characterized by the presence of complex chronic conditions (e.g., intractable epilepsy, degenerative neurologic disease) that are expected to last at least 12 months and require subspecialty care or tertiary care hospitalizations, CMC often require treatment with complex polypharmacy to sustain quality of life and control substantial symptom burden [1–11]. Pediatric polypharmacy is shown to increase the risk of medication-related problems (MRPs) [11–28]. A MRP is an event involving medication therapy that interferes with an optimum patient outcome, for example, an inappropriate therapy, undertreated symptom, major drug–drug interaction, or adverse drug event (ADE) [12, 13, 16–28]. These types of MRPs are defined, measurable, and potentially treatable if recognized [12, 13, 16–29]. Although MRPs are associated with patient morbidity and healthcare utilization, polypharmacy is infrequently assessed during routine clinical care for CMC, and MRPs are managed ad hoc [10, 30–33].

While polypharmacy is often necessary for symptom and disease management in CMC, opportunities for improved outpatient medication management are ubiquitous [10, 30–33]. Current pediatric polypharmacy management strategies are fragmented and reactive, rather than proactive [34]. CMC are often prescribed medications by multiple sub-specialists and lack a coordinating medication supervisor [8]. Isolated medication regimen reviews may occur when CMC experience acute healthcare changes or ADEs [33]. In contrast, the Centers for Medicare & Medicaid Services requires Medicare sponsors to provide preventive medication therapy management (MTM) programs to targeted adult patients [35]. Standardized pharmacist-led MTM activities (e.g., medication optimization, deprescribing, education) are patient-centric, comprehensive, and improve health outcomes and safety [35–41].

Numerous potential benefits of a systematic approach to MTM-like services in an analogous pediatric population have been described. In a study of 100 CMC with

polypharmacy in the ambulatory setting, an average of 3.4 MRPs were identified per patient, with 97% of patients having opportunities for potential intervention [12]. Most frequently proposed interventions included drug discontinuation trials, caregiver education, dose modification, and modification of dosage form or frequency to reduce medication regimen complexity. In a separate, health system-wide initiative focused on medication list reviews within a broad pediatric population, a group of ambulatory clinical pharmacists performed 409 interventions over a 6-month pilot period, most frequently involving the management of asthma, infections, or pain [42]. The majority of interventions resulted in full resolution of identified MRPs, but the authors described a need for further investigation to determine the value-based sustainability of the program.

In the priority population of CMC, the additional administrative complexity of polypharmacy regimens may introduce further risks and opportunities for benefit of MTM services, particularly those focused on medication simplification where appropriate. In a study of 123 pediatric patients with neurological impairment and polypharmacy, patients' medication regimens included a median of 31 total doses of medication, 6 unique dosage forms, 7 different dosing frequencies, and 5 medications with additional administration specifications (e.g., split/crush tablet, open capsule for administration via g-tube) per patient [4]. Safety and effectiveness of these regimens is therefore highly dependent on caregiver understanding and ability. In a study of 156 caregivers of CMC, most parents were highly involved in home medication administration, but some reported concerns about medication administration and safety [9]. Of all caregivers, only 73% were able to correctly match a medication to its targeted symptoms, 60% were able to report complete dosing instructions, and 55% were able to correctly measure liquid medication doses. Significant differences existed between caregivers' perceived understanding of such abilities versus demonstrated task performance. Related concerns have been described by parents and investigators elsewhere [15, 34, 43].

### Major knowledge gaps and research needs

In 2021, the Joint Commission Sentinel Event Alert highlighted the dire need for “additional research on

interventions to reduce pediatric medication errors, especially in emergency departments, ambulatory clinics and home environments” [44]. Despite a robust body of prior research demonstrating the risks of pediatric polypharmacy, rigorously tested pediatric-specific interventions to manage polypharmacy-related issues are scarce and greatly needed [10, 30–33]. Complex care programs that provide comprehensive care to CMC have identified pharmacy support as a preeminent need [33]. While medication safety is a priority for pediatric complex care programs, a systematic intervention will not be widely adopted without demonstrated effectiveness and value for CMC [45]. Pharmacists may provide targeted reactive pharmaceutical care in the existing model, but proactive comprehensive care is needed [42, 46–49]. Pediatric pharmacy specialists currently provide support in multiple hospital settings, but pediatric pharmacists are infrequently incorporated into outpatient models of care for CMC [32, 42, 46, 47, 50]. However, a more central role has been proposed for outpatient pediatric pharmacists in the medical home to coordinate and manage medication regimens, and to support primary care providers (PCPs) [33, 48, 51]. Furthermore, parental acceptance of this model is high; in the previous study of 156 parents of CMC with polypharmacy, 87% were willing to change  $\geq 1$  medication(s) if recommended by their provider [9].

As care models evolve, thoughtful incorporation of proactive and preventative evidence-based strategies into the management of pediatric polypharmacy is necessary to improve medication-related patient outcomes, safety, and value. Pharmacist-led MTM is a proven and effective tool for managing adult and geriatric polypharmacy [35–41]. The overarching aim of this trial is to determine if a structured pharmacist-led Pediatric Medication Therapy Management (pMTM) intervention will improve the proactive management of polypharmacy in CMC by directly addressing major gaps in current practice.

### **An approach for improving the management of pediatric polypharmacy**

We propose a rigorous and efficient hybrid type 2 trial with evaluation of pMTM guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework [52] with the following specific aims:

*Aim 1:* Assess Reach and Effectiveness by determining the effect of a pMTM intervention on the primary outcome of total MRPs among CMC with polypharmacy, as well as the secondary outcomes of parent-reported symptoms and acute healthcare utilization, compared to usual care. We hypothesize that pMTM will result in lower MRP counts, stable or

improved symptom burdens, and fewer cumulative acute healthcare encounters compared to usual care.

*Aim 2:* Determine how key patient and parent factors modify pMTM Effectiveness through quantitative measurement of the effect modification of patient/parent factors on the primary MRP outcome, as well as through qualitative parental report. We hypothesize that higher medical complexity and higher parental health literacy will be associated with a larger treatment effect.

*Aim 3:* Evaluate provider pMTM Adoption, Implementation, and potential for Maintenance through assessment of actual provider adoption, fidelity/time requirements, qualitative provider perceptions (including feasibility, acceptability, and barriers or facilitators), and assessment of program replication costs.

Through a systematic approach, the results of this pMTM trial will inform the medical community on the value and effectiveness of pMTM towards optimization of polypharmacy among the priority population of CMC.

## **Methods/Design**

### **Protocol reporting**

This protocol has been prepared according to the RE-AIM framework (Table 1) and the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Statement (Table 2) [52–54]. Trial results will be reported according to the Consolidated Standards of Reporting Trials (CONSORT) and the Consolidated Criteria for Reporting Qualitative Research (COREQ) guidelines [55–57]. This trial was registered at clinicaltrials.gov (NCT05761847) on 02/25/2023. The SPIRIT Checklist is provided as Additional File 1.

### **Trial design**

This trial is a 5-year hybrid type 2 randomized controlled trial funded by the Agency for Healthcare Research and Quality (AHRQ) and designed to evaluate the management of pediatric polypharmacy in the primary care setting by comparing the pMTM intervention to usual care for lowering the primary outcome of MRP counts and secondary outcomes of symptom burdens and acute healthcare utilization. Because pediatric pharmacist support is currently a limited resource, a hybrid type 2 design is the most efficient, rigorous design to simultaneously evaluate the effectiveness and implementation of pMTM to enable rapid dissemination [58]. The intervention is not blinded to enrolled patients; however, study team members involved in assessment of outcomes, data analysis, and safety monitoring will be blinded.

**Table 1** Outcome measures and measurement strategies using the RE-AIM framework

		Outcome Measure	How We Will Measure (Data Source)
<b>Aim</b>	<b>Reach</b>	1. CMC with polypharmacy who participate in pMTM	1. % and representativeness of patients who participate vs. decline (EHR)
<b>1</b>	<b>Effectiveness</b>	1. <b>Medication-Related Problems (MRPs)</b> 2. Parent-Reported Outcomes of Symptoms (PRO-Sx) 3. Acute healthcare utilization	1. <b>MRP count at 90 days (EHR)</b> 2. PRO-Sx total symptom score (parent) 3. Acute visit count at 90 days (EHR)
<b>2</b>	<b>Effect Modification</b>	MRP count associated with: 1. Patient medical complexity 2. Parent health literacy 3. Barriers/facilitators of parental implementation	1. ICD-10-CM codes (EHR) 2. Short Assessment of Health Literacy (parent) 3. Qualitative interviews (parent)
<b>3</b>	<b>Adoption</b>	1. Providers' participation in pMTM	1. % and representativeness of those who participate vs. decline (annual survey)
	<b>Implementation</b>	1. Fidelity of key pMTM components 2. Time required by providers to implement pMTM 3. Providers' perceived barriers/facilitators of pMTM implementation	1. Audio-recorded encounters (audio) 2. Time spent on medication-related activities during clinical visit (audio) 3. Qualitative interviews (provider)
	<b>Maintenance</b>	1. Healthcare teams' perceptions of and intentions regarding continuing pMTM following the trial 2. Overall pMTM replication program costs	1. Interviews with providers and leadership 2. Time-driven activity-based costing related to implementation and maintenance of pMTM relative to usual care costs

All study procedures were reviewed and approved by the affiliated Institutional Review Board (IRB). Protocol amendments will be approved by the local IRB. Other pertinent parties will be notified through updates to the clinicaltrials.gov website. All publications related to the study will include a summary of protocol amendments.

### Study setting, participants, and eligibility criteria

Study enrollment is scheduled to begin in August 2023 and will occur through September 2027. The study will take place at the Special Care Clinic (SCC) at Children's Hospital Colorado, a large multidisciplinary primary care medical home for CMC within a large, tertiary, freestanding children's hospital. Patients ages 2–18 years old with  $\geq 1$  complex chronic condition and  $\geq 5$  concurrent medications (including prescription, as needed, and over-the-counter medications), and their primary parental caregiver will be screened for inclusion [5]. Patients with a non-English speaking primary caregiver will be excluded, as the pMTM intervention and certain study instruments are currently available only in English. Females and males and members of all racial and ethnic categories will be included if eligible, without bias.

### Randomization, allocation, and study phases

Eligibility screening will be conducted by trained research personnel using automated daily electronic health record (EHR) reporting tools that identify eligible children with a scheduled routine clinical visit in the SCC within the next 14 days. Following review of eligibility criteria, research personnel will contact the caregiver to introduce the study, invite the caregiver (and assenting adolescents) to participate, and obtain written consent.


Following consent, research personnel will work with study participants to complete baseline and 90-day assessments using EHR functionality. Baseline assessment will include patient and parent demographics, assessment of health literacy, assessment of parent attitudes towards deprescribing, and parental assessment of symptom burden (Table 2). Using the current EHR medication list, all participants will undergo medication history review with a study team member trained using WHO's Standard Operation Protocol [59]; data will be collected for research purposes only, but if significant medication safety concerns are noted, the study team will alert the primary care provider (PCP) before the clinical visit. All additional data will be conducted during subsequent study and clinical visits.

Participants will then be randomized 1:1 in permuted blocks of 4 patients to pMTM intervention or usual care (2 patients to each arm), with the pMTM intervention occurring  $\leq 3$  days before a scheduled well child visit or routine follow-up medical encounter (Fig. 1). Those randomized to intervention will meet with a study pharmacist (PharmD) in-person or via telehealth for completion of the pMTM encounter (described comprehensively below). Both groups will then be seen for their scheduled PCP visit as occurring within usual care. After the clinical visit, all participants will receive the post-clinical visit medication list and, for those in the intervention arm, the medication action plan (MAP). Participants will be followed for 90 days after the clinical visit to track the primary, secondary, and exploratory outcomes (Tables 2 and 3).

**Table 2** Enrollment, interventions, and assessments according to the Standard Protocol Items: Recommendations for Intervention Trials (SPIRIT) diagram

		Study period			
	Enrollment	Allocation & Baseline	Study Visit	Clinic Visit	90-day Follow Up
Timepoint (Days):	-14 to -3	-14 to -3	-3 to 0	0	90
<b>Enrollment:</b>					
Eligibility screen	X				
Informed consent	X				
Allocation		X			
<b>Interventions:</b>					
pMTM Intervention			↔	↔	↔
Usual Care			↔	↔	↔
<b>Primary outcomes:</b>					
Medication-Related Problem (MRP) Count					X
<b>Secondary outcomes:</b>					
Parent-Reported Outcomes of Symptoms (PRO-SX)			X	X	X
Unplanned ER visits, hospitalizations				X	X
<b>Additional assessments:</b>					
Demographics – Patient & Parent		X			
Short Assessment of Health Literacy (SAHL-E/S) – Parent		X			
Patients' Attitudes Towards Deprescribing – Parent		X			X
Patient Health Questionnaire-9 (PHQ-9) – Parent		X			X
Burden Scale for Family Caregivers (BSFC) – Parent		X			X
<b>Medication safety:</b>					
Potential Drug-Drug Interaction Counts (DrugBank)			X	X	X
High-Alert Medication Counts			X	X	X
Medication Adherence (ARMS)			X	X	X
Adverse Drug Reactions			X	X	X
<b>Exploratory outcomes:</b>					
Medication Regimen Complexity Index (MRCI) Score			X	X	X
Medication Counts			X	X	X





**Fig. 1** Study Flow Diagram. Protocolized study flow is depicted. Following enrollment and consent, participants will be randomized 1:1 to pMTM intervention or usual care, with the pMTM intervention occurring  $\leq 3$  days before a scheduled well child visit or routine follow-up medical encounter. Both groups will then be seen for their scheduled PCP visit as occurring within usual care. Applicable outcomes will be re-assessed at 90-day follow-up

**Table 3** Assessments and outcomes supporting pMTM effectiveness aims

Minimum Data Elements for Aims 1 & 2
<b>Baseline Assessments:</b> <ul style="list-style-type: none"><li>• Demographics – Patient &amp; Parent</li><li>• Complex Chronic Conditions (ICD-10) [5] – EHR</li><li>• Medication history – EHR, Parent</li><li>• Short Assessment of Health Literacy (SAHL-E) [63] – Parent</li></ul>
<b>Primary Outcome at 90 Days:</b> <ul style="list-style-type: none"><li>• Medication-related problem count [12] – EHR, Parent</li></ul>
<b>Secondary Outcomes at 90 Days:</b> <ul style="list-style-type: none"><li>• Parent-Reported Outcomes of Symptoms (PRO-Sx) [7]</li><li>• Acute healthcare utilization visit count [1, 13] – EHR</li></ul>
<b>Exploratory Outcomes at 90 Days:</b> <ul style="list-style-type: none"><li>• Medication Regimen Complexity Index Scores [4]—EHR</li><li>• Medication counts [1]—EHR</li></ul>

**Treatments**

**Intervention: pMTM conceptual framework**


The trial design is conceptualized based on the Shed-MEDS model of deprescribing, which posits that adult patients with potentially inappropriate polypharmacy will benefit from a patient-centered deprescribing intervention to reduce polypharmacy and improve health [60]. With permission, the model is modified to include the broader core activity of pMTM, during which parents and providers review medication changes, continuation, proper use, monitoring, and follow-up (Fig. 2) [30, 60]. For CMC with polypharmacy, our model specifies that the pMTM intervention (which accounts for and prioritizes safety, quality of life, and parental considerations)

will lead to patient-centered optimization of medications [4, 30, 61].

**Intervention: pediatric medication therapy management steps**

Following baseline patient and caregiver assessments, patients randomized to the intervention will take part in a PharmD visit for application of the pMTM intervention, occurring in person or via telehealth within 3 days prior to the planned PCP clinical visit. The pMTM intervention will be applied during a 30- to 45-min visit in which the PharmD will work collaborative with the caregiver to complete 3 major activities (Table 4).

First, the PharmD will perform with the patient and caregiver a comprehensive medication review (CMR) of the patient’s current personal medication list (PML). CMR is a systematic process of collecting patient-specific data and assessing for potential medication-related problems. Subsequent clinical decisions are reliant on accuracy of available data; therefore, the first step of CMR is to conduct a thorough medication history using all available resources, updating the patient’s PML where necessary, and documenting that such activities have occurred. The PharmD will gather a list of active medications (including prescriptions, over-the-counter medications, dietary supplements, and complementary medicines), determine and confirm active disease states, and identify providers involved in the prescribing and management of current medication therapy. Next, the PharmD will review each disease therapy with the caregiver and patient, if appropriate, to determine current goals of therapy. Caregiver understanding of goals of therapy is



**Fig. 2** Conceptual Framework for pMTM Intervention. This protocol is conceptualized based on the SHED-MEDS model of deprescribing [60]. With permission, we modified this model with the broader core activity of pMTM, during which parents and providers review medication changes, continuation, proper use, monitoring, and follow-up. For children with polypharmacy, our model specifies that the pMTM intervention (which accounts for and prioritizes safety, quality of life, and parental considerations) will lead to patient-centered optimization of medications, resulting in improved health and symptoms manifest as fewer MRPs [4, 12, 30].

**Table 4** Components of comprehensive pMTM Intervention

Major Activity	Specific Components	Duration
Comprehensive review of medication regimen	<ol style="list-style-type: none"> <li>1. Update medication list</li> <li>2. Review patient/caregiver goals for each therapy</li> <li>3. Confirm adherence or identify barriers to adherence (e.g., cost, taste aversion, difficult administration)</li> <li>4. Review current effectiveness for any targeted symptoms or lab values</li> <li>5. Identify therapeutic duplication and/or potentially unnecessary therapies</li> <li>6. Review for potentially medication-attributable symptoms or adverse effects</li> </ol>	10–15 min
Optimization of medication regimen	<ol style="list-style-type: none"> <li>1. With caregiver, identify list of ongoing concerns – could be ADEs, symptoms perceived to be undertreated, less-than-ideal administration schedule. <i>Prioritize this list according to (1) safety, (2) patient quality of life, (3) caregiver/family quality of life</i></li> <li>2. Formulate plan for medication adjustment (e.g., dose optimization, schedule change, formulation change), discontinuation, or initiation to address above issues. <i>May be list of medication changes today or a detailed plan for recommendations to take back to a subspecialist</i></li> <li>3. Include expectations for both subjective monitoring and objective labs or tests (e.g., ECG) that will be necessary/recommended, with expected timeline</li> </ol>	10–15 min
Creation of medication action plan	<ol style="list-style-type: none"> <li>1. Caregiver-friendly medication list (directly populated from EHR)</li> <li>2. Bulleted list of current changes (to make today) and planned changes</li> <li>3. Plan for follow-up with pharmacist or another provider</li> </ol>	5–10 min

important to their ability to provide confident care to CMC. Education related to mismatch of therapy goals and known medication effects may be addressed at this time. Additionally, the PharmD will determine if any barriers may be affecting adherence. Barriers to adherence in

CMC often include taste aversion, difficult or confusing administration techniques, burdensome dosing schedule, or medication cost, among others. Such barriers may be addressed in subsequent steps of the pMTM intervention. Following review of therapy goals and adherence,

the PharmD will evaluate any available laboratory data and discuss ongoing clinical symptoms to determine current medication effectiveness or lack thereof. The PML will be appraised for potential therapeutic duplication and therapies for which resolution of symptoms may render ongoing treatment unnecessary. Common examples of duplication of therapy within this population include use of multiple NSAID agents or acetaminophen-containing products or use of multiple medications within the same therapeutic class (e.g., clonidine and guanfacine). Such duplication may cause potentiation of adverse effects or contribute to excessive medication costs without conferring additional therapeutic benefit. As the final component of CMR, the PharmD will review current patient symptoms to identify those which may be attributable to medication use or toxicity, which may result in recommendations for alternative therapy or deprescribing. Gaps in therapy for guideline-directed care of various disease states (e.g., asthma) may also be identified at this stage.

The second essential element of the pMTM intervention involves optimization of the medication regimen to address those concerns or opportunities identified within the preceding CMR. With the caregiver, a list of all ongoing concerns will be prioritized according to goals of therapy. Considerations related to safety, patient quality of life, and caregiver or family quality of life will be measured during this process and communicated within subsequent recommendations for medication optimization. Next, the PharmD will formulate a plan for recommended medication-related changes, including potential dose or frequency adjustment, discontinuation of therapy, or initiation of alternate medications to manage untreated or ongoing disease symptoms. Recommendations will be classified according to type (Table 5), and rationale will be provided. All recommendations will be included in a structured pMTM provider note within the EHR which is intended to be informative and suggestive, as well as concise and respectful. Recommendations may be provided in the form of changes recommended for urgent action by the PCP (at the impending clinic visit) or communication with subspecialists for those

diseases states primarily managed by alternate providers. Expectations and recommendations for both subjective monitoring and objective labs or tests (e.g., ECG) will be communicated to the caregiver and documented within the structured pMTM provider note. Any medications changes recommended during the visit will ultimately be made at the discretion of the PCP during clinical care.

As the final component of the pMTM intervention, after the clinical visit, the PharmD will create a written, patient-centered, and caregiver-friendly MAP using a template populated from the EHR. This MAP will describe a prioritized list of specific action items resulting from the interactive pMTM consultation, which empowers the caregiver to be personally involved in the administration of the proposed optimization(s). The document was developed from the CMS standardized format to allow for tracking of patient progress, clarification of intended patient response, and documentation of the perceived clinical effects of all changes [62]. The MAP is designed assist the caregiver with resolving current drug therapy concerns and to help achieve the goals of medication treatment but is not intended to provide the level of detailed communication provided to the PCP or other healthcare providers. Items reinforcing compliance, maintaining caregiver actions, and acknowledging success in the child's medication therapy may be included. The caregiver will be encouraged to bring the MAP with them to future healthcare visits and to request update of the document as necessary. A plan for follow-up all changes with the PharmD of other appropriate providers will be outlined within the MAP and communicated to the caregiver. Additionally, the reconciled PML (created within the CMR stage of the pMTM visit) will be provided to the caregiver to assist in the understanding of current medication treatment and the tracking of potential medication changes, such as addition of over-the-counter medications or redaction of discontinued products. Information about appropriate disposal of unneeded medications will be provided by the PharmD if applicable.

**Control group: usual care**

Patients randomized to usual care will undergo medication history review performed by study personnel prior to the PCP clinical visits as previously described. The goal of this medication review process is to ensure accuracy of the baseline medication-related data without recommendations related to medication management. We selected a usual care comparator because there are no current established standards for centralized medication management strategies within the population of CMC. All medications decisions for the control group are at the discretion of the PCP.

**Table 5** Types of interventions recommended within pMTM intervention

Modification (dose, form, frequency)
Discontinuation
Change to alternative therapy
Initiation of new therapy
Laboratory monitoring for safety/efficacy
Patient/caregiver education



**Study measures and data collection**

Table 2 includes all study measures and data collection time points. To promote study retention, participants will receive compensation in the form of \$50 gift cards at two study time-points (i.e., completion of clinical visit and at 90 days). Each study measure listed in Table 2 is briefly described below.

**Demographics, health literacy, and attitudes towards medication management**

Research personnel will use a standardized approach to extract information from the EHR related to basic patient demographics (age, gender, complex chronic conditions, level of polypharmacy). Complex chronic condition data is generated using the CCC V2 published classification system based on ICD-10 diagnosis codes [5]. Prior work has demonstrated that CMC with some complex chronic conditions, such as technology dependence (e.g., tracheostomy dependence, gastrostomy tube), may be exposed to higher levels of polypharmacy, and subsequent analysis will seek to determine if the medical complexity of CMC is associated with varying trial outcomes [1].

Caregiver health literacy will be assessed through parental completion of the Short Assessment of Health Literacy (SAHL-E) [63]. This test consists of 18 items, for which participants are instructed to read a medical term aloud before associating each term to another word with similar meaning to demonstrate comprehension. In this study, scores > 14 will indicate adequate health literacy, while scores ≤ 14 will indicate inadequate health literacy. Studies of medication management in adults have demonstrated a clear link between health literacy and medication self-management skills [64, 65]. Parents with different levels of health literacy may have different levels of engagement with the pMTM intervention, especially because medication optimization is comprised of multiple activities and not solely medication discontinuation. Ultimately, interventions to manage polypharmacy must support parents of all levels of health literacy [66-73]. While the pMTM intervention uses patient-centric communication modalities, understanding differences in the outcome by level of parental health literacy will guide post-trial refinements.

Finally, attitudes toward medication management will be assessed through parental completion of the Patients' Attitudes Toward Deprescribing (PATD) tool [74]. This scoring system consists of 15 items used to classify the participant's feelings towards polypharmacy, their own medication history, and comfort with discontinuation of medications.

**Primary outcome measure: medication-related problems**

The primary outcome is the MRP count at 90 days after the clinical visit during which the PCP finalizes

any clinical recommendations for either the pMTM intervention or usual care groups. Because medication changes require time to effect change in clinical outcomes, we will collect outcome measurements at 90 days after the clinical visit, consistent with adult literature using the MRP outcome [12, 13, 16-28]. Robust evidence exists to support the utility of using MRPs as an outcome to evaluate MTM. As related to this outcome, we will follow established guidelines for analyzing and reporting composite measures [75-77]. To facilitate blinded assessment of MRPs, we will generate an EHR-based clinical summary at 90 days, including the current weight, active medication list, symptom report, lab values, serum levels, and any diagnostic codes related to ADEs (Table 6). Trained study personnel will contact parents to verify the medication history, symptom data, and any adverse events or acute healthcare utilization. Blinded outcome assessments will be made by ≥ 2 pediatric pharmacists not involved in the pMTM intervention using our published standardized approach [61].

**Secondary outcome measures: Parent-Reported Outcomes of Symptoms (PRO-Sx), and healthcare utilization**

We will also measure changes in total parent-reported outcomes of symptoms (PRO-Sx) scores and 90-day acute healthcare utilization for both the intervention and usual care groups [6, 7, 78]. To ensure that symptoms are stable or improved after medication changes, we will track PRO-Sx scores, which we have experience measuring among CMC in the ambulatory setting [6, 7, 78]. Based on our prior work, it is feasible for parents to easily track symptoms from home via EHR functionality [6, 7, 78]. This will occur at scheduled time points, including the date of the pMTM visit for patients allocated to the intervention group, the date of the PCP clinical visit for all patients, and at 7 days, 30 days, and 90 days following the clinical visit. As part of the 90-day clinical summary, we will track counts of unplanned acute care utilization, including ambulatory sick visits, emergency room visits, and inpatient hospitalizations.

**Table 6** Common medication-related problems in children with medical complexity

Inappropriate or unnecessary therapy
Suboptimal therapy
Undertreated symptoms
Adverse drug event
Contraindicated drug-drug interaction
Duplication of therapy
Unclear prescription instructions

### **Exploratory outcomes and safety measures**

During the 90-day follow up period, we will assess additional exploratory outcomes including Medication Regimen Complexity Index (MRCI) scores and medication counts for all medications, including scheduled, as needed, and over-the-counter medications [79]. MRCI, a tool developed to measure medication complexity in adult and geriatric populations with polypharmacy, has demonstrated potential for application in pediatric populations and has been associated with increased acute healthcare utilization [4, 61, 80–82]. In addition to the previously described patient-level PRO-Sx symptom burden scores, parental completion of the Patient-Health Burden Scale for Family Caregivers (BSFC) and Patient Health Questionnaire (PHQ-9) will be performed at scheduled time points to measure caregiver burden and mental health [83, 84].

In addition to assessment of ADEs as described within the MRP primary outcome, several other measures of medication safety and adherence will be collected. First, the DrugBank database will be interrogated against baseline and 90-day patient medication lists for potential drug-drug interaction count [85]. High-alert medication counts will be assessed using published guidance from the Institute for Safe Medication Practices [86]. Finally, medication adherence will be measured using the Adherence to Refills and Medications Scale (ARMS) at similar study time points [87].

### **Additional outcomes within RE-AIM framework**

As defined within the RE-AIM framework of the study design, the aims of this study will address several goals which are not formally captured by the primary and secondary outcomes defined above, which primarily measure pMTM effectiveness. The outcomes that will be used to assess the impact of the pMTM intervention towards other aims are described briefly below:

**Reach** Reach of the pMTM intervention will be quantified by measuring the percentage and representativeness of CMC with polypharmacy who accept and decline participation in the pMTM intervention. Study personnel will track the patients and parents declining participation, including previously defined demographics and reasons for non-participation.

**Effect modification** Previously described variables of medical complexity, health literacy, and attitudes towards medication management will be assessed at the patient- and parent-level, where appropriate, to quantitatively evaluate intervention effect modification. To qualitatively evaluate effect modification, we will conduct a semi-structured interviews through the study period with a

total of 40 caregivers. Qualitative interviews will include 10 caregivers from each subgroup (technology dependent/independent and high/low health literacy); only caregivers who participated in the pMTM intervention arm will be included. To recruit for this portion of the study, participating parents will receive a \$25 gift card. A trained professional qualitative study team member will conduct recorded 1-h parent interviews via phone or video software. Qualitative interview guides will be pilot tested prior to use with study subjects. The guide will elicit parents' perceptions of the feasibility, acceptability, and barriers/facilitators of the pMTM intervention, specifically focusing on how outcomes may have been impacted by their health literacy and whether their child was dependent on specific forms of technology. Recruitment for qualitative caregiver interviews will discontinue if ongoing analysis (described below) reveals thematic saturation [88].

**Adoption, implementation, and maintenance** To measure PCP adoption of the pMTM intervention, short annual confidential surveys will be administered to quantify adoption of the pMTM intervention and recommendations by clinical providers, as well satisfaction and time spent related to pMTM. The study team will pilot test and monitor surveys to identify potential problems that could result in missing responses. Providers will be encouraged to complete all items on the survey, informed of the negative impact of missing data on the research, and assured that their answers are completely confidential. Those who participate will receive a \$10 gift card after completing each annual survey. We will calculate the percentage and representativeness of eligible providers involved in the pMTM intervention and attempt to collect reasons for declination if observed.

Implementation fidelity will be evaluated through audio recording of a sample of visits from the intervention arm (pMTM visit and corresponding clinical visit) and the usual care arm (clinical visit). We will screen and recruit participants for recording of visits using permuted block randomization for a total of 100 audio-recorded encounters (50 encounters per arm). For in-person visits, study personnel will start the recorder and leave the room. The parent, child, or provider can stop recordings at any point. For telehealth-based pMTM study visits, audio recording will occur within the software. The audio-recorded clinical encounters will be used to compare whether the provider addresses pMTM-related components (medication review, optimizations, and action plan) during the clinical visits (binary outcome), and to estimate the time needed to implement the pMTM intervention or discuss medication-related issues (continuous

outcome), focusing on differences between pMTM and usual care.

To measure aims related to pMTM maintenance, we will conduct 15 qualitative interviews with consented providers at time points including the beginning, middle, and end of the trial, for a total of 45 interviews. To reduce bias, we will attempt to interview all providers at least once during the study period. We will also attempt to interview some providers (specifically the pharmacists) at >1 time point to evaluate how their experience with pMTM changed over time. Qualitative interview guides will be pilot tested prior to use with study subjects. We will elicit providers' perceptions of the feasibility, acceptability, and barriers/facilitators of the pMTM intervention. At the final time point, we will specifically focus on providers' perceptions and intentions of sustaining the interventions following the completion of the trial. Providers who participate in an interview will receive a \$50 gift card. Recruitment will discontinue if ongoing analysis (described below) reveals thematic saturation [88].

Finally, to measure maintenance outcomes related to program replication costs, we will use time-driven activity-based costing approach to measure the cost related to implementation and maintenance of pMTM relative to usual care costs. Using best practices, we will develop process maps for patient/parent flow for both pMTM and usual care delivery and specify care activities and who (pharmacist, provider, other clinic staff) performs each activity [89]. The largest component of cost will be the time clinic staff devote to delivering pMTM and usual care, which we will measure using the audio recordings of clinical visits, annual surveys (questions about average time spent for pre-clinical visit preparation and post-visit documentation), and provider interviews (to explore reasons for variation) described above. Measures of time will be converted to cost using internal salaries and fringe benefits for each category of clinic staff. We will also value time using Bureau of Labor Statistics data to estimate more representative replication costs [90]. We will obtain cost information for other clinic and informatics resources directly and indirectly supporting the adoption, implementation, and maintenance of pMTM [91, 92].

### Blinding

Due to the nature of the pMTM intervention, patient, pharmacist, and PCP participants are not blinded to the intervention. Investigators and statisticians performing data analysis will be blinded to subject allocation. Additionally, participants involved in assessment of safety measures and pediatric pharmacists involved in assignment of the MRP primary outcome will be blinded to patient group assignment.

### Statistical methods

Patient and parent characteristics in both study arms will be evaluated using appropriate measures of central tendency and spread for continuous variables and proportions for categorical variables. For the primary MRP outcome analysis, we will assess for differences in MRP counts between the intervention and control groups at 90 days using generalized linear models with Poisson response distribution and log link function. The overall effectiveness of the intervention will be assessed by testing the model coefficient for randomization group, with a null hypothesis of no mean difference in MRP counts at 90 days between treatment and control groups. Model checking and diagnostics will be performed to assess validity of model assumptions, with appropriate remedial measures taken as necessary. For the secondary outcome analysis, we will assess for differences in outcome changes over time between the intervention and control groups using generalized linear mixed models, which accounts for correlation between repeated outcome measurements over time. Within-subjects correlation will be accounted for using a random intercept.

Towards assessment of patient and parent factors modifying pMTM effectiveness, we will employ similar generalized linear mixed models. Each of the pre-specified effect modifiers will be modeled as an interaction term between the intervention variable (binary) and the effect modifier variable (binary). The test of the null hypothesis that the interaction term's coefficient is equal to 0 will indicate whether there is evidence that the effectiveness of the intervention varies according to the proposed modifier.

Towards implementation fidelity, comparisons focusing on differences between the intervention and usual care arms will be made using generalized linear mixed models with logistic link and a random intercept for provider to account for correlation within providers. Comparisons in time, focusing on whether there is a difference between arms in the time a provider spends addressing medication-related issues, will be made using linear mixed models, with a random intercept for provider to account for correlation within providers.

For analysis of program implementation and replication costs, our primary measures of cost will be the average amount of time of clinic staff devoted to the pMTM intervention and usual care and the average cost per-patient for pMTM and usual care. The average time will be calculated for each category of clinic staff, including the pharmacist, by the mean time measured in the audio recordings plus the mean time reported in the annual surveys. The average cost per-patient will convert the average time measures to dollars using Bureau of Labor Statistics data and add in the cost of other clinic resources

divided by the number of patients. We will also conduct a sensitivity analysis using different time measures based on the distribution of the time measures across the audio recordings and survey responses.

For all qualitative data, we will employ qualitative content analysis throughout the periods of data collection and analysis [88, 93]. This is appropriate as our goal is to explore the participants' experiences, focusing on their perceptions of the pMTM intervention and the feasibility and acceptability of the intervention. To achieve this, we will use an inductive coding process in which 2+ research team members independently develop codes and their definitions through reading the transcripts. The team will discuss their respective codes to develop a consolidated codebook. The study team will then independently apply the codebook to the next set of transcripts, and then meet and reconcile their codebooks and coded data. This process will continue until a final codebook is agreed upon. The final codebook will be applied to the remaining transcripts. Coded transcripts will be entered into Atlas.ti version 9.1 for analysis, and we will develop themes that capture the major concepts about feasibility, acceptability, and barriers/facilitators of the pMTM intervention.

#### Missing data and intent-to-treat

In the event of missing data, we will examine the data to determine if omission varies by study arm. However, our approach using mixed effects regression modeling will provide accurate estimates and inference in the presence of missing data under certain assumptions. We will check these assumptions and, if necessary, perform sensitivity analyses to quantify the effect of missing outcome data on our results. All outcomes will be analyzed on an intention-to-treat basis.

#### Preservation of type-1 error rate

The overall effectiveness of the intervention will be assessed using a multiple degree-of-freedom test with a null hypothesis of no difference between study arms at 90 days post-randomization. Based on our prior studies of pediatric medication regimen complexity, we will adjust for potential confounders including patient age, number of complex chronic conditions, and recent acute healthcare utilization. All quantitative analyses will be performed in Stata 17.0 (College Station, TX). We will use a 2-sided significance level of 0.05 for all hypothesis testing; thus, the type-I error rate for the assessment of overall effectiveness is fixed at 5%. Standard errors and 95% confidence intervals will also be reported.

#### Power and sample size

The overall effectiveness of the intervention will be evaluated based on the primary outcome measure, total MRP count. Based on our previous medication safety studies in SCC, we anticipate enrolling 80% of eligible participants and collecting data from  $\geq 80\%$  of enrolled participants at the 90-day follow up. We will approach 463 potential participants and enroll 371 to achieve a final analytic sample size of 296 children and their parents. This will provide  $>90\%$  power at the 2-sided 0.05 significance level to detect a 1.0 difference between study arms in MRP count, which is sufficient to detect clinically meaningful changes demonstrated by our pilot data. If there is some degree of contamination between the intervention arms due to clinicians seeing patients in both arms, the study will maintain 80% power to detect a significant mean difference in the primary outcome; this assumes a dilution of the treatment effect of 15% (i.e., that the difference in mean outcomes between treatment arms is attenuated to 0.85). These calculations assume a standard deviation in the MRP outcome of 2.6 as determined through prior work in this area. The proposed sample size will also provide adequate power to detect clinically important changes in quantitative secondary outcomes at the 2-sided 0.05 significance level. Assuming a correlation of 0.4 within patients, the study will have 80% power to detect a difference between study arms in mean change of a) PRO-Sx symptom scores by 3.1 points and b) counts of acute healthcare utilization by 0.8–1.1 visits. These calculations assume a correlation of each outcome within patients of 0.4.

To achieve implementation fidelity aims using audio-taped visits, additional sample size and power calculations were performed. With a total of 50 audiotaped visits per study arm, the study will have 80% power to detect a 0.23 difference in proportions if fidelity in the pMTM group is 90%. The study will also have 80% power to detect a mean difference of 2.8 min if the standard deviation of the length of the conversation is 5 min. Correlation within providers will be accounted for by a mixed effects model's random intercept.

#### Data integrity and privacy

This project will produce a variety of data types across the five years of the project. All study data will be collected by trained research personnel during each study phase. Study data will be collected and analyzed from 4 primary sources, including (1) EHR data, (2) prospectively collected patient- and parent-reported data, (3) study visit data, and (4) transcripts from parent and provider interviews. Clinical data will be extracted from the EHR and/or patient charts. Throughout the trial, EHR data will be queried for utilization, pharmacy, and clinical



outcome data. We do not anticipate the collection of any paper documents. Raw data will be transformed using REDCap data management tools and the subsequent processed dataset used for statistical analysis. REDCap is a secure, web-based application designed to support data entry, validation and management. Designated research staff will review REDCap data monthly to ensure data completeness and quality. To protect research participant identities and based on ethical and legal considerations, only de-identified individual data will be made available for sharing. All study data will be retained for a minimum preservation time of 3 years. The preservation time will be extended such that resulting publications have been publicly available for at least 12 months before retiring any data. Data will be made available upon request to the larger research community as soon as possible or at the time of associated publication.

#### **Access to data and dissemination policy**

All investigators will have access to the trial's final dataset. There are no contractual agreements that limit such access. The investigators intend to publish results for all pre-specified primary and secondary outcomes in the peer-reviewed literature, including publication of the study protocol and access to statistical code upon request for review. Dissemination is key to ensuring that any evidence-based practices elucidated from our study can result in substantial improvements in management of pediatric polypharmacy beyond the study's immediate scope. Study materials, tools, and resources will be developed so that they may be easily adapted to other settings, with particular focus on creation of an implementation and adaptation guide and online training module. Should the pMTM intervention prove effective, we intend to leverage ongoing research partnerships and collaborate with additional sites to test the pMTM intervention on a broader scale.

#### **Data and safety monitoring board**

The study's principal investigator (JAF) will have overall responsibility for the Data Safety and Monitoring Plan and for participant safety monitoring. As we are studying only the pediatric-implementation of MTM, an evidence-based practice recommended and widely provided for adult and geriatric enrollees with polypharmacy, the risks to human subjects are minimal. Furthermore, any medication-related optimizations made as part of the pMTM intervention are implemented based on joint decision making between the patient, parent, and the PCP during the routine clinical visit. Although minimal risks to human subjects are anticipated and a formal data safety monitoring board is not required, we will take robust precautions to

monitor study participants for signal of adverse events or unanticipated problems during the study according to AHRQ requirements.

#### **Discussion**

Optimal health for the priority population of CMC often depends on the chronic use of multiple medications in the outpatient setting. In all populations, MRPs resulting from polypharmacy can lead to potentially devastating outcomes, and CMC are indeed more vulnerable to MRPs. For example, in a study of 144 million pediatric emergency department visits, CMC were approximately 5 times more likely to experience an ADE-related emergency visit [13]. In the outpatient setting, CMC may also have undertreated symptoms, receive suboptimal pharmacotherapy, or experience preventable adverse effects [4, 6, 7, 94]. While pediatric polypharmacy is prevalent, current polypharmacy management strategies are fragmented and reactive, and medication safety initiatives remain a high priority for pediatric complex care programs [33]. The medication-related and overall health outcomes associated with an MTM program for pediatric patients are unknown, particularly as these relate to CMC. We propose that a pMTM intervention by pediatric pharmacists could, through patient-centered medication regimen simplification and tailored caregiver support, address MRPs and result in increased parental confidence and medication understanding, thereby improving medication safety and effectiveness.

Real and potential limitations of the study do exist. First, enrollment plans were established in alignment with our prior medication safety studies, in which enrollment occurred at a rate of approximately 100 patient-parent pairs per year [4, 6, 7]. If recruitment is slower than planned, we will work with the local family advisory council to alter our recruitment protocol. Also, if the intervention and study instruments are expanded to other languages during the study period, we will include these additional populations. Second, because participant blinding cannot be achieved for the pMTM intervention, participants who do not receive the intervention may leave the study early, potentially biasing results. We will provide small incentives to retain study participants. Also, all study personnel participating in assessment of outcomes, data analysis, and safety monitoring will be blinded. Third, as described above, the risk of contamination is low, but our total sample size accounts for a worst-case scenario of a 15% reduction in treatment effect from contamination. Finally, while we include CMC from a large urban and rural catchment area, this may not be representative of all CMC. To inform generalizability, we will compare enrolled CMC with national data.

The pMTM study is the first randomized controlled trial to evaluate a centralized, coordinated, and comprehensive approach to medication management in CMC with polypharmacy. The results of this trial will quantify the impact of the pMTM intervention on medication safety, effectiveness, and overall medication complexity. Additionally, this trial will examine the impact of pMTM on subsequent acute healthcare utilization by CMC. Through the described systematic approach, the results of this trial will inform the pediatric medical community on the value and effectiveness of pMTM towards optimization of medication therapy among CMC with polypharmacy.

### Trial status

We anticipate that trial recruitment will begin in August 2023 and will be completed by September 2027. The trial protocol is currently active in its original version without revision.

### Abbreviations

ADE	Adverse drug event
AHRQ	Agency for Healthcare Research and Quality
ARMS	Adherence to Refills and Medications Scale
BSFC	Burden Scale for Family Caregivers
CMC	Children with medical complexity
CMR	Comprehensive medication review
ECG	Electrocardiogram
EHR	Electronic health record
IRB	Institutional review board
MAP	Medication action plan
MRCI	Medication Regimen Complexity Index
MRP	Medication-related problem
MTM	Medication therapy management
NSAID	Non-steroidal anti-inflammatory drug
PATD	Patients' Attitudes Toward Deprescribing
PCP	Primary care provider
PharmD	Study pharmacist
PHQ-9	Patient Health Questionnaire-9
PML	Personal medication list
PRO-Sx	Parent-Reported Outcomes of Symptoms
SAHL-E	Short Assessment of Health Literacy-English
SCC	Special Care Clinic

### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12913-023-09439-y>.

**Additional file 1.** SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents.

### Acknowledgements

We acknowledge the clinical staff in the Children's Hospital Colorado Special Care Clinic, who will participate in the conduct of this study.

### Authors' contributions

JAF conceptualized the overall study and all authors made substantial contributions to the design of the study. LEO, CF, AK, SL, and JAF designed the study intervention. JAF drafted the study protocol and all authors revised and approved the final study protocol. JAF obtained funding for the study. LEO

drafted the manuscript and all authors revised and approved the final version of the manuscript. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

### Funding

This research study was funded by the Agency for Healthcare Research and Quality through award R01HS028979 made to the Principal Investigator Dr. Feinstein. The use of the institutional data management system REDCap is supported by NIH/NCATS Colorado CTSA Grant Number UL1 TR002535. The funders have no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. This was the first study related manuscript submitted for publication. The content is solely the responsibility of the authors and does not represent the official views of the Agency for Healthcare Research and Quality or the U.S. government.

### Availability of data and materials

Not applicable.

### Declarations

#### Ethics approval and consent to participate

Ethics approval was granted by the Colorado Multiple Institutional Review Board (COMIRB #22–2423 and #23–0109). Written informed consent will be obtained from all patients and their legal guardian(s). Written assent of pediatric patients will also be obtained using an assent form for children ages 7–12 years old and a joint assent-consent form for children ages 13–18 years old. All experiments will be performed in accordance with relevant guidelines and regulations including the Declaration of Helsinki.

#### Consent for publication

Not applicable.

#### Competing interests

The authors declare that they have no competing interests.

#### Author details

<sup>1</sup>Skaggs School of Pharmacy & Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. <sup>2</sup>Department of Pharmacy, Children's Hospital Colorado, Aurora, CO, USA. <sup>3</sup>Division of General Pediatrics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. <sup>4</sup>Departments of Pediatrics and Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. <sup>5</sup>Adult & Child Center for Outcomes Research & Delivery Science (ACCORDS), University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, 1890 N. Revere Court, 3Rd Level, Mail Stop F443, Aurora, CO 80045, USA. <sup>6</sup>Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. <sup>7</sup>Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. <sup>8</sup>Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. <sup>9</sup>Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, USA.

Received: 15 March 2023 Accepted: 24 April 2023

Published online: 29 April 2023

### References

- Feinstein JA, Feudtner C, Valuck RJ, Kempe A. The depth, duration, and degree of outpatient pediatric polypharmacy in Colorado fee-for-service Medicaid patients. *Pharmacoepidemiol Drug Saf.* 2015;24(10):1049–57. <https://doi.org/10.1002/pds.3843>. (Epub 20150807. PubMed PMID: 26248529).
- Feudtner C, Dai D, Hexem KR, Luan X, Metjian TA. Prevalence of polypharmacy exposure among hospitalized children in the United States. *Arch Pediatr Adolesc Med.* 2012;166(1):9–16. <https://doi.org/10.1001/archpediatrics.2011.161>. (Epub 20110905. PubMed PMID: 21893637).

3. Feinstein JA, Hall M, Antoon JW, Thomson J, Flores JC, Goodman DM, Cohen E, Azuine R, Agrawal R, Houtrow AJ, DeCoursey DD, Kuo DZ, Collier R, Gaur DS, Berry JG. Chronic Medication Use in Children Insured by Medicaid: A Multistate Retrospective Cohort Study. *Pediatrics*. 2019;143(4). <https://doi.org/10.1542/peds.2018-3397>. Epub 2019/03/28. PubMed PMID: 30914443; PMCID: PMC6456893.
4. Feinstein JA, Friedman H, Orth LE, Feudtner C, Kempe A, Samay S, Blackmer AB. Complexity of Medication Regimens for Children With Neurological Impairment. *JAMA Netw Open*. 2021;4(8):e2122818. <https://doi.org/10.1001/jamanetworkopen.2021.22818>. (Epub 20210802. PubMed PMID: 34436607; PMCID: PMC8391103).
5. Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation. *BMC Pediatr*. 2014;14:199. <https://doi.org/10.1186/1471-2431-14-199>. (Epub 20140808. PubMed PMID: 25102958; PMCID: PMC4134331).
6. Feinstein JA, Feudtner C, Blackmer AB, Valuck RJ, Fairclough DL, Holstein J, Gregoire L, Samay S, Kempe A. Parent-Reported Symptoms and Medications Used Among Children With Severe Neurological Impairment. *JAMA Netw Open*. 2020;3(12):e2029082. <https://doi.org/10.1001/jamanetworkopen.2020.29082>. (Epub 20201201. PubMed PMID: 33306117; PMCID: PMC7733159).
7. Feinstein JA, Feudtner C, Valuck RJ, Fairclough DL, Holstein JA, Samay S, Kempe A. Identifying Important Clinical Symptoms in Children With Severe Neurological Impairment Using Parent-Reported Outcomes of Symptoms. *JAMA Pediatr*. 2020;174(11):1114–7. <https://doi.org/10.1001/jamapediatrics.2020.2987>. (Epub 2020/10/13. PubMed PMID: 33044500; PMCID: PMC7551220).
8. Feinstein JA, Rodean J, Hall M, Doupanik SK, Gay JC, Markham JL, Bettenhausen JL, Simmons J, Garrity B, Berry JG. Outpatient Prescription Opioid Use in Pediatric Medicaid Enrollees With Special Health Care Needs. *Pediatrics*. 2019;143(6). <https://doi.org/10.1542/peds.2018-2199>. Epub 2019/05/30. PubMed PMID: 31138667; PMCID: PMC6626319.
9. Blackmer AB, Fox D, Arendt D, Phillips K, Feinstein JA. Perceived Versus Demonstrated Understanding of the Complex Medications of Medically Complex Children. *J Pediatr Pharmacol Ther*. 2021;26(1):62–72. <https://doi.org/10.5863/1551-6776-26.1.62>. (Epub 20210104. PubMed PMID: 33424502; PMCID: PMC7792139).
10. Feinstein JA, Morrato EH, Feudtner C. Prioritizing Pediatric Drug Research Using Population-Level Health Data. *JAMA Pediatr*. 2017;171(1):7–8. <https://doi.org/10.1001/jamapediatrics.2016.3462>. (Epub 2016/11/29. PubMed PMID: 27893067).
11. Feinstein J, Dai D, Zhong W, Freedman J, Feudtner C. Potential drug-drug interactions in infant, child, and adolescent patients in children's hospitals. *Pediatrics*. 2015;135(1):e99–108. <https://doi.org/10.1542/peds.2014-2015>. (Epub 20141215. PubMed PMID: 25511114).
12. Marquez C, Thompson R, Feinstein JA, Orth LE. Identifying opportunities for pediatric medication therapy management in children with medical complexity. *Journal of the American Pharmacists Association: JAPhA*. 2022. <https://doi.org/10.1016/j.japh.2022.04.005>. Epub 20220412. PubMed PMID: 35527209.
13. Feinstein JA, Feudtner C, Kempe A. Adverse drug event-related emergency department visits associated with complex chronic conditions. *Pediatrics*. 2014;133(6):e1575–85. <https://doi.org/10.1542/peds.2013-3060>. (Epub 20140519. PubMed PMID: 24843054).
14. Zandieh SO, Goldmann DA, Keohane CA, Yoon C, Bates DW, Kaushal R. Risk factors in preventable adverse drug events in pediatric outpatients. *J Pediatr*. 2008;152(2):225–31. <https://doi.org/10.1016/j.jpeds.2007.09.054>. (Epub 20071119. PubMed PMID: 18206693).
15. Walsh KE, Mazor KM, Stille CJ, Torres I, Wagner JL, Moretti J, Chysna K, Stine CD, Usmani GN, Gurwitz JH. Medication errors in the homes of children with chronic conditions. *Arch Dis Childhood*. 2011;96(6):581–6. <https://doi.org/10.1136/adc.2010.204479>. (Epub 20110327. PubMed PMID: 21444297).
16. Touchette DR, Stubbings J, Schumock G. Improving Medication Safety in High Risk Medicare Beneficiaries Toolkit. Rockville, MD: Agency for Healthcare Research and Quality; 2012. p. 38.
17. Lim XY, Yeo QQ, Kng GLL, Chung WL, Yap KZ. Validation of a Drug-Related Problem Classification System for the Intermediate and Long-Term Care Setting in Singapore. *Pharmacy (Basel)*. 2018;6(4). <https://doi.org/10.3390/pharmacy6040109>. Epub 20181003. PubMed PMID: 30282930; PMCID: PMC6306714.
18. American Society of Hospital Pharmacists. Draft statement on pharmaceutical care ASHP Council on Professional Affairs American Society of Hospital Pharmacists. *Am J Hosp Pharm*. 1993;50(1):126–8 (PubMed PMID: 8427270).
19. Willoch K, Blix HS, Pedersen-Bjergaard AM, Eek AK, Reikvam A. Handling drug-related problems in rehabilitation patients: a randomized study. *Int J Clin Pharm*. 2012;34(2):382–8. <https://doi.org/10.1007/s11096-012-9623-5>. (Epub 20120303. PubMed PMID: 22388601).
20. Pharmaceutical Care Network Europe. Classification for drug related problems V9.1 2020. Available from: [https://www.pcne.org/upload/files/417\\_PCNE\\_classification\\_V9-1\\_final.pdf](https://www.pcne.org/upload/files/417_PCNE_classification_V9-1_final.pdf).
21. Sugioka M, Tachi T, Mizui T, Koyama A, Murayama A, Katsuno H, Matsuyama T, Aoyama S, Osawa T, Noguchi Y, Yasuda M, Goto C, Teramachi H. Effects of the number of drugs used on the prevalence of adverse drug reactions in children. *Sci Rep*. 2020;10(1):21341. <https://doi.org/10.1038/s41598-020-78358-3>. (Epub 20201207. PubMed PMID: 33288793; PMCID: PMC7721890).
22. Masica AL, Touchette DR, Dolor RJ, Schumock GT, Kliethermes MA, Rodgers PT, Craft JL, Choi YK, Lux LJ, Smith SR. Evaluation of a Medication Therapy Management Program in Medicare Beneficiaries at High Risk of Adverse Drug Events: Study Methods. In: Henriksen K, Battles JB, Keyes MA, Grady ML, editors. *Advances in Patient Safety: New Directions and Alternative Approaches (Vol 4: Technology and Medication Safety)*. Rockville (MD)2008.
23. Touchette DR, Masica AL, Dolor RJ, Schumock GT, Choi YK, Kim Y, Smith SR. Safety-focused medication therapy management: a randomized controlled trial. *J Am Pharm Assoc* (2003). 2012;52(5):603–12. <https://doi.org/10.1331/JAPhA.2012.12036>.
24. Woodall T, Landis SE, Galvin SL, Plaut T, Roth McClurg MT. Provision of annual wellness visits with comprehensive medication management by a clinical pharmacist practitioner. *Am J Health Syst Pharm*. 2017;74(4):218–23. <https://doi.org/10.2146/ajhp150938>. (PubMed PMID: 28179248).
25. Ploenzke C, Kemp T, Naidl T, Marraffa R, Bolduc J. Design and implementation of a targeted approach for pharmacist-mediated medication management at care transitions. *J Am Pharm Assoc* (2003). 2016;56(3):303–9. <https://doi.org/10.1016/j.japh.2016.01.009>. (Epub 20160414. PubMed PMID: 27150224).
26. Moczygemba LR, Goode JV, Gatewood SB, Osborn RD, Alexander AJ, Kennedy AK, Stevens LP, Matzke GR. Integration of collaborative medication therapy management in a safety net patient-centered medical home. *J Am Pharm Assoc* (2003). 2011;51(2):167–72. <https://doi.org/10.1331/JAPhA.2011.10191>. (PubMed PMID: 21382806; PMCID: PMC3280342).
27. Isetts BJ, Schondelmeyer SW, Artz MB, Lenarz LA, Heaton AH, Wadd WB, Brown LM, Cipolle RJ. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. *J Am Pharm Assoc* (2003). 2008;48(2):203–14. <https://doi.org/10.1331/JAPhA.2008.07108>. (PubMed PMID: 18359733).
28. Smith SM, Wallace E, O'Dowd T, Fortin M. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. *Cochrane Database Syst Rev*. 2016;3:CD006560. <https://doi.org/10.1002/14651858.CD006560.pub3>. (Epub 20160314. PubMed PMID: 26976529; PMCID: PMC6703144).
29. Lea M, Mowe M, Mathiesen L, Kvernrod K, Skovlund E, Molden E. Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward. *PLoS One*. 2019;14(7):e0220071. <https://doi.org/10.1371/journal.pone.0220071>. (Epub 20190722. PubMed PMID: 31329634; PMCID: PMC6645516).
30. Bogler O, Roth D, Feinstein J, Strzelecki M, Seto W, Cohen E. Choosing medications wisely: Is it time to address paediatric polypharmacy? *Paediatr Child Health*. 2019;24(5):303–5. <https://doi.org/10.1093/pch/pxy188>. (Epub 20190105. PubMed PMID: 31379430; PMCID: PMC6656947).
31. Carpenter D, Gonzalez D, Retsch-Bogart G, Sleath B, Wilfond B. Methodological and Ethical Issues in Pediatric Medication Safety Research. *Pediatrics*. 2017;140(3). <https://doi.org/10.1542/peds.2017-0195>. Epub 20170804. PubMed PMID: 28778857; PMCID: PMC5574727.
32. Huth K, Hotz A, Starmer AJ. Patient Safety in Ambulatory Pediatrics. *Current Treatment Options in Pediatrics*. 2020;6(4):350–65. <https://doi.org/10.1007/s40746-020-00213-4>.

33. Huth K, Vandecruys P, Orkin J, Patel H. Medication safety for children with medical complexity. *Paediatr Child Health*. 2020;25(7):473–4. <https://doi.org/10.1093/pch/pxaa105>. (Epub 20201102. PubMed PMID: 33178368; PMCID: PMC7606167).
34. El-Rachidi S, LaRoche JM, Morgan JA. Pharmacists and Pediatric Medication Adherence: Bridging the Gap. *Hosp Pharm*. 2017;52(2):124–31. <https://doi.org/10.1310/hpj5202-124>. (Epub 2017/03/23. PubMed PMID: 28321139; PMCID: PMC5345910).
35. Centers for Medicare & Medicaid Services. Medication Therapy Management 2022. Available from: <https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/MTM>.
36. Centers for Disease Control and Prevention. Community Pharmacists and Medication Therapy Management Washington, DC2021. Available from: <https://www.cdc.gov/dhdp/pubs/guides/best-practices/pharmacist-mtm.htm>.
37. Ryan R, Santesso N, Lowe D, Hill S, Grimshaw J, Pricot M, Kaufman C, Cowie G, Taylor M. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. *Cochrane Database Syst Rev*. 2014;4:CD007768. <https://doi.org/10.1002/14651858.CD007768.pub3>. (Epub 20140429. PubMed PMID: 24777444; PMCID: PMC6491214).
38. Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS, Cave A, Chang WC, Dzavik V, Farris KB, Galvin D, Semchuk W, Taylor JG. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). *Archives of internal medicine*. 2002;162(10):1149–55. <https://doi.org/10.1001/archinte.162.10.1149>. (Epub 2002/05/22. PubMed PMID: 12020186).
39. American College of Clinical P, McBane SE, Dopp AL, Abe A, Benavides S, Chester EA, Dixon DL, Dunn M, Johnson MD, Nigro SJ, Rothrock-Christian T, Schwartz AH, Thrasher K, Walker S. Collaborative drug therapy management and comprehensive medication management-2015. *Pharmacotherapy*. 2015;35(4):39–50. <https://doi.org/10.1002/phar.1563>. (Epub 2015/04/18. PubMed PMID: 25884536).
40. Brummel A, Carlson AM. Comprehensive Medication Management and Medication Adherence for Chronic Conditions. *J Manage Care Pharm*. 2016;22(1):56–62. <https://doi.org/10.18553/jmcp.2016.22.1.56>. (Epub 2016/03/26. PubMed PMID: 27015052).
41. Agency for Healthcare Research and Quality. Health Literacy Tools for Providers of Medication Therapy Management 2020. Available from: <https://www.ahrq.gov/health-literacy/improve/pharmacy/medication-mgt.html>.
42. Sneed G, Kappeler K, Gilmore T, Kuhn C. Implementation of a medication therapy management collaborative within a pediatric health system. *J Am Pharm Assoc* (2003). 2018;58(4S):S114–9. <https://doi.org/10.1016/j.japh.2018.04.021>. (Epub 20180602. PubMed PMID: 29871801).
43. You MA, Nam SM, Son YJ. Parental Experiences of Medication Administration to Children at Home and Understanding of Adverse Drug Events. *J Nurs Res*. 2015;23(3):189–96. <https://doi.org/10.1097/jnr.0000000000000080>. (Epub 2015/02/28. PubMed PMID: 25723125).
44. The Joint Commission. Preventing pediatric medication errors 2021; 39[Available from: <https://www.jointcommission.org/resources/patient-safety-topics/sentinel-event/sentinel-event-alert-newsletters/sentinel-event-alert-issue-39-preventing-pediatric-medication-errors/#.YoascC-B1qs>.
45. Feinstein JA, Berry JG, Feudtner C. Intervention research to improve care and outcomes for children with medical complexity and their families. *Curr Probl Pediatr Adolesc Health Care*. 2021;51(12):101126. <https://doi.org/10.1016/j.cppeds.2021.101126>. (Epub 20220105. PubMed PMID: 34996708; PMCID: PMC8825706).
46. Schenk A, Eckardt-Felmsberg R, Steinhagen-Thiessen E, Stegemann S. Patient behaviour in medication management: Findings from a patient usability study that may impact clinical outcomes. *Br J Clin Pharmacol*. 2020;86(10):1958–68. <https://doi.org/10.1111/bcp.13946>. (Epub 20190523. PubMed PMID: 30937937; PMCID: PMC7495276).
47. Turner K, Buu J, Kuzel M, Wagoner EV, Berrett GB. Early Implementation of Comprehensive Medication Management within an Academic Medical Center Primary Care Pharmacy Team. *Innov Pharm*. 2020;11(2). <https://doi.org/10.24926/ipp.v11i2.3002>. Epub 20200430. PubMed PMID: 34007602; PMCID: PMC8051911.
48. Woepel J, Clark R, Underwood L, Gatwood J, Turner K, Renfro C, Hohmeier KC. The Tennessee medication therapy management program: A hybrid type 2 effectiveness-implementation trial study protocol. *Res Social Adm Pharm*. 2020;16(3):315–20. <https://doi.org/10.1016/j.sapharm.2019.05.018>. (Epub 20190524. PubMed PMID: 31151919).
49. Bradley CL, Luder HR, Beck AF, Bowen R, Heaton PC, Kahn RS, Mansour M, Obszarski S, Frede SM. Pediatric asthma medication therapy management through community pharmacy and primary care collaboration. *J Am Pharm Assoc*. 2016;56(4):455–60. <https://doi.org/10.1016/j.japh.2016.03.007>. (Epub 20160527. PubMed PMID: 27245855).
50. McFarland MS, Ourth H, Frank D, Mambourg S, Tran M, Morreale A. Development and validation of a systematic process for expansion of clinical pharmacy activities for comprehensive medication management in primary care within the Department of Veterans Affairs. *J Am Coll Clin Pharm*. 2021;4(9):1126–33. <https://doi.org/10.1002/jac5.1449>. (PubMed PMID: WOS:000662894900001).
51. Benavides S, Madzhidova S, Hernandez A, Le T, Palma SM, Stephen S. Establishment of Pediatric Medication Therapy Management: A Proposed Model. *Pharmacy (Basel)*. 2016;4(1). <https://doi.org/10.3390/pharmacy4010005>. Epub 20160119. PubMed PMID: 28970378; PMCID: PMC5419360.
52. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. *Am J Public Health*. 1999;89(9):1322–7. <https://doi.org/10.2105/ajph.89.9.1322>. (Epub 1999/09/04. PubMed PMID: 10474547; PMCID: PMC1508772).
53. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krolez-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med*. 2013;158(3):200–7. <https://doi.org/10.7326/0003-4819-158-3-201302050-00583>. (PubMed PMID: 23295957; PMCID: PMC5114123).
54. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR, Krolez-Jeric K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586. <https://doi.org/10.1136/bmj.e7586>. (Epub 20130108. PubMed PMID: 23303884; PMCID: PMC3541470).
55. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMC Med*. 2010;8:18. <https://doi.org/10.1186/1741-7015-8-18>. (Epub 20100324. PubMed PMID: 20334633; PMCID: PMC2860339).
56. Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P, Group CN. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Ann Intern Med*. 2017;167(1):40–7. <https://doi.org/10.7326/M17-0046>. (Epub 20170620. PubMed PMID: 28630973).
57. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*. 2007;19(6):349–57. <https://doi.org/10.1093/intqhc/mzm042>. (Epub 20070914. PubMed PMID: 17872937).
58. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. *Medical care*. 2012;50(3):217–26. <https://doi.org/10.1097/MLR.0b013e3182408812>. (Epub 2012/02/09. PubMed PMID: 22310560; PMCID: PMC3731143).
59. Abdellatif A, Bagian JP, Barajas ER, Cohen M, Cousins D, Denham CR, Essinger K, Gegelashvili G, Glenister H, Hoffman C, Horvath D, Khoja T, Klazinga N, Lee CE, Letlape TK, Lilja B, Manasse HR, Massoud MR, Wilson RM, Medici AC, Mohammad AJ, Munier WB, Murphy M, Murphy ML, Ortiz Z, Pinakiewicz DC, Pittet D, Reznikovich S, Rudolph B, Sheridan SE, Siu-fai L, Solomon RP, Svensson PG, Whittaker S, Youngson R. Assessing Medication Accuracy at Transitions in Care. *Joint Commission J Qual Patient Safety*. 2007;33(7):450–3. [https://doi.org/10.1016/s1553-7250\(07\)33131-0](https://doi.org/10.1016/s1553-7250(07)33131-0).
60. Vasilevskis EE, Shah AS, Hollingsworth EK, Shotwell MS, Mixon AS, Bell SP, Kripalani S, Schnelle JF, Simmons SF, Shed MT. A patient-centered deprescribing intervention for hospitalized older patients with polypharmacy: rationale and design of the Shed-MEDS randomized controlled trial. *BMC Health Serv Res*. 2019;19(1):165. <https://doi.org/10.1186/s12913-019-3995-3>. (Epub 20190314. PubMed PMID: 30871561; PMCID: PMC6416929).
61. Marquez C, Thompson R, Feinstein JA, Orth LE. Identifying opportunities for pediatric medication therapy management in children with medical complexity. *J Am Pharm Assoc*. 2022. <https://doi.org/10.1016/j.japh.2022.04.005>. Epub 20220412. PubMed PMID: 35527209.



62. Services. CfMM. Medicare Part D medication therapy management program standardized format 2013. Available from: <https://www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovcontra/downloads/mtm-program-standardized-format-pdf>.
63. Lee SY, Stucky BD, Lee JY, Rozier RG, Bender DE. Short Assessment of Health Literacy-Spanish and English: a comparable test of health literacy for Spanish and English speakers. *Health Serv Res*. 2010;45(4):1105–20. <https://doi.org/10.1111/j.1475-6773.2010.01119.x>. (Epub 20100524. PubMed PMID: 20500222; PMCID: PMC2910571).
64. Kripalani S, Henderson LE, Chiu EY, Robertson R, Kolm P, Jacobson TA. Predictors of medication self-management skill in a low-literacy population. *J Gen Intern Med*. 2006;21(8):852–6. <https://doi.org/10.1111/j.1525-1497.2006.00536.x>. (Epub 2006/08/03. PubMed PMID: 16881946; PMCID: PMC1831567).
65. Bell SP, Schnipper JL, Goggins K, Bian A, Shintani A, Roumie CL, Dalal AK, Jacobson TA, Rask KJ, Vaccarino V, Gandhi TK, Labonville SA, Johnson D, Neal EB, Kripalani S. Pharmacist Intervention for Low Literacy in Cardiovascular Disease Study G. Effect of Pharmacist Counseling Intervention on Health Care Utilization Following Hospital Discharge: A Randomized Control Trial. *J Gen Intern Med*. 2016;31(5):470–7. <https://doi.org/10.1007/s11606-016-3596-3>.
66. Erickson SR, LeRoy B. Health literacy and medication administration performance by caregivers of adults with developmental disabilities. *J Am Pharm Assoc*. 2015;55(2):169–77. <https://doi.org/10.1331/JAPhA.2015.14101>. (Epub 2015/01/24. PubMed PMID: 25615819; PMCID: PMC4401120).
67. Yin HS, Dreyer BP, Foltin G, van Schaick L, Mendelsohn AL. Association of low caregiver health literacy with reported use of nonstandardized dosing instruments and lack of knowledge of weight-based dosing. *Ambul Pediatr*. 2007;7(4):292–8 (Epub 2007/07/31. PubMed PMID: 17660100).
68. Yin HS, Mendelsohn AL, Wolf MS, Parker RM, Fierman A, van Schaick L, Bazan IS, Kline MD, Dreyer BP. Parents' medication administration errors: role of dosing instruments and health literacy. *Arch Pediatr Adolesc Med*. 2010;164(2):181–6. <https://doi.org/10.1001/archpediatrics.2009.269>. (Epub 2010/02/04. PubMed PMID: 20124148).
69. Yin HS, Parker RM, Sanders LM, Mendelsohn A, Dreyer BP, Bailey SC, Patel DA, Jimenez JJ, Kim KA, Jacobson K, Smith MCJ, Hedlund L, Meyers N, McFadden T, Wolf MS. Pictograms, Units and Dosing Tools, and Parent Medication Errors: A Randomized Study. *Pediatrics*. 2017;140(1). <https://doi.org/10.1542/peds.2016-3237>. (Epub 2017/08/02. PubMed PMID: 28759396; PMCID: PMC5495522).
70. Dahmash DT, Shariff ZB, Kirby DJ, Terry D, Huynh C. Literature review of medication administration problems in paediatrics by parent/caregiver and the role of health literacy. *BMJ Paediatr Open*. 2020;4(1):e000841. <https://doi.org/10.1136/bmjpo-2020-000841>. (Epub 20201126. PubMed PMID: 33305018; PMCID: PMC7692990).
71. Bazaldúa OV, Davidson DA, Zurek A, Kripalani S. Health Literacy and Medication Use. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. *Pharmacotherapy: A Pathophysiologic Approach*, 10e. New York, NY: McGraw-Hill Education; 2017.
72. Kripalani S, Jacobson TA, Mugalla IC, Cawthon CR, Niesner KJ, Vaccarino V. Health literacy and the quality of physician-patient communication during hospitalization. *J Hosp Med*. 2010;5(5):269–75. <https://doi.org/10.1002/jhm.667>. (Epub 2010/06/10. PubMed PMID: 20533572; PMCID: PMC3468649).
73. Boyle J, Speroff T, Worley K, Cao A, Goggins K, Dittus RS, Kripalani S. Low Health Literacy Is Associated with Increased Transitional Care Needs in Hospitalized Patients. *J Hosp Med*. 2017;12(11):918–24. <https://doi.org/10.12788/jhm.2841>. (Epub 20170920. PubMed PMID: 29091980).
74. Reeve E, Low LF, Shakib S, Hilmer SN. Development and Validation of the Revised Patients' Attitudes Towards Deprescribing (rPATD) Questionnaire: Versions for Older Adults and Caregivers. *Drugs Aging*. 2016;33(12):913–28. <https://doi.org/10.1007/s40266-016-0410-1>. (Epub 2016/10/28. PubMed PMID: 27785734).
75. National Quality Forum. Composite Performance Measure Evaluation. Washington, DC: National Quality Forum; 2013. Available from: [http://www.qualityforum.org/Publications/2013/04/Composite\\_Performance\\_Measure\\_Evaluation\\_Guidance.aspx](http://www.qualityforum.org/Publications/2013/04/Composite_Performance_Measure_Evaluation_Guidance.aspx).
76. Centers for Medicare & Medicaid Services. Composite Measures for Accountability Programs 2022. Available from: <https://mmshub.cms.gov/sites/default/files/Composite-Measures-Accountability.pdf>.
77. Barclay M, Dixon-Woods M, Lyratzopoulos G. The problem with composite indicators. *BMJ Qual Saf*. 2019;28(4):338–44. <https://doi.org/10.1136/bmjqs-2018-007798>. (Epub 20180812. PubMed PMID: 30100565; PMCID: PMC6559782).
78. Feinstein JA, Feudtner C, Kempe A, Orth LE. Anticholinergic Medications and Parent-Reported Anticholinergic Symptoms in Neurologically Impaired Children. *J Pain Symptom Manage*. 2023;65(2):e109–14. <https://doi.org/10.1016/j.jpainsymman.2022.10.013>. (Epub 20221102. PubMed PMID: 36332769; PMCID: PMC9840664).
79. George J, Phun YT, Bailey MJ, Kong DC, Stewart K. Development and validation of the medication regimen complexity index. *Ann Pharmacother*. 2004;38(9):1369–76. <https://doi.org/10.1345/aph.1D479>. (Epub 20040720. PubMed PMID: 15266038).
80. Hirsch JD, Metz KR, Hosokawa PW, Libby AM. Validation of a patient-level medication regimen complexity index as a possible tool to identify patients for medication therapy management intervention. *Pharmacotherapy*. 2014;34(8):826–35. <https://doi.org/10.1002/phar.1452>. (Epub 20140620. PubMed PMID: 24947636; PMCID: PMC4260116).
81. Schoonover H, Corbett CF, Weeks DL, Willson MN, Setter SM. Predicting potential postdischarge adverse drug events and 30-day unplanned hospital readmissions from medication regimen complexity. *J Patient Safety*. 2014;10(4):186–91. <https://doi.org/10.1097/PTS.0000000000000067>. (Epub 2014/11/20. PubMed PMID: 25408236).
82. Tjugum SL, Hansen BK, McKinzie CJ. Association of Medication Regimen Complexity With Clinical Endpoints in Pediatric Patients With Cystic Fibrosis. *J Pediatr Pharmacol Ther*. 2021;26(3):248–52. <https://doi.org/10.5863/1551-6776-26.3.248>. (Epub 20210331. PubMed PMID: 33833625; PMCID: PMC8021245).
83. Pendergrass A, Malnis C, Graf U, Engel S, Graessel E. Screening for caregivers at risk: Extended validation of the short version of the Burden Scale for Family Caregivers (BSFC-s) with a valid classification system for caregivers caring for an older person at home. *BMC Health Serv Res*. 2018;18(1):229. <https://doi.org/10.1186/s12913-018-3047-4>. (Epub 20180402. PubMed PMID: 29609600; PMCID: PMC5880098).
84. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606–13. <https://doi.org/10.1046/j.1525-1497.2001.016009606.x>. (Epub 2001/09/15. PubMed PMID: 11556941; PMCID: PMC1495268).
85. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res*. 2018;46(D1):D1074–82. <https://doi.org/10.1093/nar/gkx1037>. (Epub 2017/11/11. PubMed PMID: 29126136; PMCID: PMC5753335).
86. Institute for Safe Medication Practices. High-Alert Medications in Community/Ambulatory Settings. Available from: <https://www.ismp.org/recommendations/high-alert-medications-community-ambulatory-list>.
87. Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. *Value Health*. 2009;12(1):118–23. <https://doi.org/10.1111/j.1524-4733.2008.00400.x>. (Epub 2009/11/17. PubMed PMID: 19911444).
88. Creswell JW, Poth CN. Qualitative inquiry & research design : choosing among five approaches. 4th ed. Los Angeles: SAGE; 2018. p. xxv, 459.
89. Cidav Z, Mandell D, Pyne J, Beidas R, Curran G, Marcus S. A pragmatic method for costing implementation strategies using time-driven activity-based costing. *Implement Sci*. 2020;15(1):28. <https://doi.org/10.1186/s13012-020-00993-1>. (Epub 20200505. PubMed PMID: 32370752; PMCID: PMC7201568).
90. U.S. Bureau of Labor and Statistics. Overview of BLS Statistics on Pay and Benefits Washington, DC: United States Department of Labor; 2022. Available from: <https://www.bls.gov/bls/wages.htm>.
91. Chapel JM, Wang G. Understanding cost data collection tools to improve economic evaluations of health interventions. *Stroke Vasc Neurol*. 2019;4(4):214–22. <https://doi.org/10.1136/svn-2019-000301>. (Epub 20191201. PubMed PMID: 32030205; PMCID: PMC6979867).
92. Eisman AB, Kilbourne AM, Dopp AR, Saldana L, Eisenberg D. Economic evaluation in implementation science: Making the business case for implementation strategies. *Psychiatry Res*. 2020;283:112433. <https://doi.org/10.1016/j.psychres.2019.06.008>. (Epub 20190607. PubMed PMID: 31202612; PMCID: PMC6898762).

93. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. *Qual Health Res.* 2005;15(9):1277–88. <https://doi.org/10.1177/1049732305276687>. (Epub 2005/10/06. PubMed PMID: 16204405).
94. Antoon JW, Hall M, Herndon A, Carroll A, Ngo ML, Freundlich KL, Stassun JC, Frost P, Johnson DP, Chokshi SB, Brown CM, Browning WL, Feinstein JA, Grijalva CG, Williams DJ. Prevalence of Clinically Significant Drug-Drug Interactions Across US Children's Hospitals. *Pediatrics.* 2020;146(5). <https://doi.org/10.1542/peds.2020-0858>. Epub 20201009. PubMed PMID: 33037121; PMCID: PMC7786820.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

